Table 1 Baseline vaccine effectiveness and efficacy of TIV with upper and lower limits, by target group
From: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate
Vaccination target group | Baseline vaccine effectiveness (%) | Lower limit of vaccine effectiveness (%) | Upper limit of vaccine effectiveness (%) | Baseline vaccine efficacy (%) | Lower limit of vaccine efficacy (%) | Upper limit of vaccine efficacy (%) | RCTs used for efficacy |
|---|---|---|---|---|---|---|---|
6 – 23 months | 59 [30] | 19.4 [32] | 65.7 [31] | 45 [33] | 25 | 65 | 2 studies, 786 recruits (525 vaccinated 261 placebo) |
Healthy, 2–64 years (health care workers and pregnant women) | 51 [30] | 41.3 [31] | 63.3 [32] | 61 [34] | 48 | 70 | 17 studies 31,325 recruits (16,213 vaccinated 15,112 placebo) |
Underlying chronic conditions, 2–64 yrs | 51 [30] | 41.3 [31] | 63.3 [32] | 61 [34] | 48 | 70 | 17 studies 31,325 recruits (16,213 vaccinated 15,112 placebo) |
Elderly | 39 [30] | 15.1 [32] | 59.9 [31] | 58 [35] | 34 | 73 | 3 studies, 2217 recruits (1,110 vaccinated 1,107 placebo) |